HIV antiretroviral prophylaxis for injecting drug users [2]

The Lancet

Volumn 382, Issue 9895, 2013, Pages 853-

  Miller, William C ^a   Hoffman, Irving F ^a   Latkin, Carl A ^b   Strathdee, Steffanie A ^c   Shoptaw, Steven ^d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; ANTIRETROVIRUS AGENT;

DIRECTLY OBSERVED THERAPY; DRUG USE; FOLLOW UP; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPROPHYLAXIS; KAPLAN MEIER METHOD; LETTER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK REDUCTION; FEMALE; MALE; NOTE; SUBSTANCE ABUSE; ANTIRETROVIRAL THERAPY; DRUG ABUSE; INCIDENCE; INFECTION PREVENTION; INJECTION DRUG ABUSE; VIRUS TRANSMISSION;

ADENINE; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; ORGANOPHOSPHONATES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84883527457     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61854-1     Document Type: Letter

References (1)

1. Choopanya K, Martin M, Suntharasamai P., et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381: 2083-90.